Acelyrin Founder Shao-Lee Lin Emerges at Cue, as It Becomes Latest to License From China
Cue Biopharma announced a strategic reboot, appointing Acelyrin founder Shao‑Lee Lin to its executive team and unveiling a new allergy drug candidate sourced from research labs in Taiwan and mainland China. The Boston‑based company, previously focused on T‑cell immunotherapies, will now leverage Lin's expertise in peptide‑based therapeutics to accelerate the development of the licensed asset. The partnership marks Cue's first formal technology transfer from China, expanding its pipeline beyond oncology. The move aims to diversify revenue streams and position Cue for upcoming FDA filings.
Asembia AXS26: How CGTs Are Reshaping Specialty Pharmacy
Cell and gene therapies (CGTs) are fundamentally changing the specialty pharmacy landscape, moving beyond traditional buy‑and‑bill models toward highly coordinated, patient‑specific workflows. The therapies demand specialized treatment‑center activities such as apheresis, conditioning, and strict cold‑chain logistics. High upfront costs create...
OP-3136
OP‑3136, a KAT6A‑selective inhibitor, entered Phase 1/2 trials for advanced hormone‑receptor‑positive breast cancer. The drug mimics the pyrophosphate of acetyl‑CoA using an acyl‑sulfonamide scaffold, delivering high specificity for the epigenetic writer KAT6A. Olema Pharmaceuticals is testing OP‑3136 in combination with SERDs...
Microbiome-Based Therapy Gains FDA Fast Track in Ulcerative Colitis
Belgium‑based MRM Health announced that its investigational microbiome‑based therapy MH002 has been granted FDA fast track designation for mild‑to‑moderate ulcerative colitis. MH002 is a live biotherapeutic composed of six defined commensal bacterial strains designed to restore gut microbial balance and...
Sydnexis to Present New Data From Phase 3 STAR Trial of SYD-101 at ARVO 2026 Annual Meeting
Sydnexis announced it will unveil new subgroup analysis data from the Phase 3 STAR trial of its low‑dose atropine eye drop SYD‑101 at the ARVO 2026 meeting in Denver. The analysis focuses on children with fast‑progressing myopia, a cohort that typically...
World Asthma Day 2026: New Anti-Inflammatory Drugs and More for Asthma Control
World Asthma Day on May 5 highlighted the persistent gap in access to anti‑inflammatory inhalers, a core theme of the Global Initiative for Asthma. The FDA approved AstraZeneca’s Breztri Aerosphere, the first single‑inhaler triple therapy that combines an inhaled corticosteroid, a...
New Semaglutide for Alcohol Use Disorder Trial Shows Big Drops in Drinking
A Lancet‑published, double‑blind, 26‑week trial found once‑weekly semaglutide markedly reduced alcohol consumption in participants with alcohol use disorder and obesity. Across primary drinking endpoints, the semaglutide arm showed statistically significant declines compared with placebo, despite both groups receiving identical cognitive‑behavioral...
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (Plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals announced that Australia’s Therapeutic Goods Administration approved REDEMPLO® (plozasiran), the first siRNA therapy for familial chylomicronemia syndrome (FCS) in the country. The drug, administered subcutaneously every three months, targets apoC‑III to dramatically lower triglycerides. In the Phase 3 PALISADE...
Policy Watch: FDA Looks to Expand Real-Time Drug Clinical Trials
The FDA has launched an AI‑driven pilot that streams clinical‑trial data in real time for AstraZeneca and Amgen’s lymphoma and lung‑cancer studies, and is now seeking public input to broaden the approach. The Ninth Circuit Court declined to compel the...
Gut Microbe’s Sulfated Bile Acid Eases Pediatric Sepsis
Researchers identified deoxycholic acid 3‑sulfate (DCA‑3S) as a gut‑derived metabolite that mitigates pediatric sepsis. Metabolomic and metagenomic analyses revealed Enterococcus raffinosus as the primary producer, accounting for over 80 % of DCA‑3S synthesis. In mouse models, DCA‑3S restored intestinal barrier integrity and dampened...
STAT+: Axsome Wins FDA Nod for Alzheimer’s Agitation
Axsome Therapeutics announced that the U.S. Food and Drug Administration has granted a regulatory nod for its investigational therapy aimed at treating agitation in Alzheimer’s disease. The agency’s decision clears the path for accelerated clinical development, potentially moving the drug...
Novel Pulsed Field Ablation Technology ‘Works’
A first‑in‑human trial of Pulse Biosciences' nanosecond pulsed‑field ablation (CellFX nsPFA 360) treated 177 patients with paroxysmal atrial fibrillation. The catheter delivered >10,000 V nanosecond pulses, achieving 100% acute lesion success and 91% durability at 2‑3 months. At one year, 89.7% of patients remained free...
Peptides Are Unproven as Health Aids. FDA May Unleash Them Anyway
The FDA is poised to broaden access to injectable peptides by allowing compounding pharmacies to produce them and by considering their inclusion in oral dietary supplements. Health and Human Services Secretary Robert F. Kennedy Jr. has publicly opposed what he...
Drug Trials Snapshot: TRYNGOLZA
TRYNGOLZA (olezarsen), an APOC‑III‑directed antisense oligonucleotide, received FDA approval on December 19, 2024 for adults with familial chylomicronemia syndrome (FCS). In the pivotal Phase 3 trial (NCT04568434), 66 patients from 11 countries received monthly 80 mg injections or placebo for 53 weeks. The drug achieved...
Programmable RNA Targeting via DNA-Guided CRISPR-Cas12a
A team of molecular biologists has reengineered the CRISPR‑Cas12a nuclease to cleave RNA using a DNA guide, creating a programmable RNA‑targeting platform. The DNA‑guided Cas12a system achieved up to 90% knockdown of endogenous transcripts in human cell lines and functioned...
Drug Trials Snapshot: ALYFTREK
Vertex Pharmaceuticals received FDA approval for ALYFTREK, a triple‑combination CFTR modulator, on Dec. 20, 2024. The drug targets cystic fibrosis patients aged six and older with at least one F508del or other responsive mutation. Approval was based on two 52‑week, non‑inferiority trials...
Drug Trials Snapshot: ROMVIMZA
Deciphera's ROMVIMZA (vimseltinib) received FDA approval on Feb 17 2025 for adult tenosynovial giant‑cell tumor (TGCT) when surgery is unsuitable. Approval was based on a global phase II trial of 123 patients, showing a 40% overall response rate versus 0% with placebo...
Rosen Law Firm Opens Securities Class Action Probe Into Disc Medicine After FDA Setback
Rosen Law Firm announced a securities class‑action investigation into Disc Medicine (NASDAQ: IRON) following an FDA Complete Response Letter that halted the company's bitopertin program and sent the stock down 22% on Feb. 13, 2026. The firm is urging shareholders to join...
Cerus Names Vivek K. Jayaraman as New COO, Raises 2026 Revenue Guidance
Cerus Corporation introduced Vivek K. Jayaraman as its incoming chief operating officer during its Q1 2026 earnings call. The leadership change coincides with a 24% jump in product revenue to $53.7 million and an upward revision of full‑year product revenue guidance...
Summit Slips on Ivonescimab's Apparent Interim Miss in Sign of Investor Frustration
Summit Therapeutics’ shares plunged almost 20% after an interim analysis of its Phase 3 trial of ivonescimab showed a statistical shortfall in a key efficacy endpoint. The miss was limited to a subgroup analysis, but investors interpreted it as a signal...
High‑dose Semaglutide Cuts Alcohol Use in RCT
Clinicians and patients saw big reductions in alcohol intake when starting GLP-1 medicine. This is the first randomized trial to look at the high dose of semaglutide. There was a study a couple years back looking at a lower dose....
Empa and HOCH Health Launch Light‑Activated Nanozyme Therapy for Brain Tumors
Empa and the HOCH Health Ostschweiz network have begun a research partnership to create a light‑activated nanozyme therapy for astrocytoma and other aggressive brain tumors. The project, funded by several Swiss foundations, targets the blood‑brain barrier challenge and plans to...
Amgen Files Update to Tavneos Label as FDA Escalates Push to Withdraw
Amgen filed a supplemental application to revise the prescribing information for its rare‑disease drug Tavneos (avacopan) as the FDA intensifies its effort to withdraw the product. The label update seeks to add new safety warnings and monitoring requirements after the...
Getein Biotech Q1 Profit Rises 18% to $10.7M as Revenue Hits $37.5M
Getein Biotech posted a first‑quarter profit of RMB76.3 million ($10.7 M), up 18% year‑over‑year, and revenue of RMB267.5 million ($37.5 M), a 9.6% increase. The results highlight accelerating demand for molecular diagnostics in China.
Amgen Positions MariTide as Potential ‘Best Monthly’ Obesity Drug
Amgen is positioning its bispecific antibody‑peptide MariTide as the premier monthly or less‑frequent obesity treatment. The company launched a Phase 3 MARITIME‑Switch study to evaluate switching patients from weekly GLP‑1 injections to four‑to‑six monthly doses. Phase 2 data showed up to a...
Finland’s Algorithmiq Takes Top Spot in $50M Q4Bio Challenge with Quantum Drug Simulation Milestone
Finland’s Algorithmiq won the $2 million prize in Wellcome Leap’s $50 million Q4Bio challenge, becoming the first to demonstrate an end‑to‑end quantum‑classical workflow for drug simulation on real hardware. Using up to 100 qubits on IBM’s quantum computer, the team modeled the...
Theradaptive Receives US FDA Approval to Initiate P-III Trial of OsteoAdapt SP for Spinal Fusion Procedures
Theradaptive has secured U.S. FDA approval to launch the pivotal OASIS Phase III trial evaluating its OsteoAdapt SP device as a bone‑graft alternative in transforaminal, anterior, and lateral lumbar interbody fusion (TLIF, ALIF, LLIF) procedures. The trial follows earlier studies involving...
Enzymatic DNA Synthesis Frees Synthetic Biology Design
“You should design for the biology you want to build, not for the process limitations of a supplier that’s been holding the field back.” That line from @Jason_Gammack , CEO of @AnsaBio , gets right to the heart of one...
Friday Hope: H. Erinaceus (Lion’s Mane): A Mushroom Which May Help Those Suffering From Long COVID/Spike Disease/Injury
The post reviews pre‑clinical data showing that Hericium erinaceus (Lion’s Mane) suppresses NF‑κB, COX‑2 and iNOS while activating Nrf2, thereby reducing inflammation, oxidative stress and supporting neuronal health. Mouse studies demonstrate improved mitochondrial membrane potential, ATP production and antioxidant enzyme...
AstraZeneca’s Breast Cancer Drug Fails to Earn Backing of FDA Advisory Committee
The FDA’s advisory committee voted against recommending AstraZeneca’s oral SERD camizestrant for HR⁺/HER2‑ metastatic breast cancer patients with an ESR1 mutation, citing concerns over the Phase 3 SERENA‑6 trial design. The study switched patients to camizestrant at the point of mutation...
Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent
Eli Lilly posted a strong Q1 2026, with revenue up 56% YoY to almost $20 billion, driven by $12.8 billion in GLP‑1 sales from Mounjaro and Zepbound. The FDA also approved Foundayo, the first oral GLP‑1 agonist for obesity that can be taken without...
ARCHIMED to Acquire Esperion Therapeutics in a $1.1 Billion Deal
ARCHIMED has agreed to acquire Esperion Therapeutics for approximately $1.1 billion, offering shareholders $3.16 in cash per share—a 58% premium—and a contingent value right (CVR) that could add up to $100 million based on future sales milestones. The transaction values Esperion at...
BIO on the American Road Tours Gene Therapy Hub in Ohio
BIO President John F. Crowley toured Ohio on April 28, spotlighting the state’s emerging gene‑therapy hub. Researchers at Nationwide Children’s Hospital have delivered two of the FDA’s first eight approved gene therapies for Duchenne muscular dystrophy and spinal muscular atrophy type 1....
Corcept Ties ALS Drug to Improved 2-Year Survival as Phase 3 Start Date Nears
Corcept Therapeutics reported that its experimental ALS drug dazucorilant reduced the two‑year risk of death by roughly 87% in a Phase 2 extension study, despite missing its primary motor‑function endpoint. The survival benefit was most pronounced at the 300 mg dose, though...
Seaport, Hemab Price IPOs, While Avalyn Soars in Nasdaq Debut
Three biotech companies priced their initial public offerings between Thursday and Friday, collectively raising more than $850 million. Seaport Therapeutics secured $225 million at $20 per share, while Hemab Therapeutics attracted $210 million at $18 per share. Avalyn Pharma led the pack with...
MDMA-Assisted Therapy for Depression: A Promising but Early First Step
A small open‑label proof‑of‑principle study examined MDMA‑assisted therapy in 12 adults with moderate‑to‑severe major depressive disorder. Participants received two MDMA dosing sessions spaced a month apart together with nine psychotherapy sessions. At two months, 75% of participants achieved remission and...
Interim Data Hint Weaker PFS; Selloff Caps Losses
Leerink's Daina Graybosch on $SMMT "... In our base case scenario of the company’s likely statistical design choices and enrollment timing, not hitting statistical significance at this interim suggests a degradation in PFS Hazard Ratio (HR) of ~10 percentage points...
ARCH Backs Mental‑health IPO, Celebrating Early Investment Success
Congrats to Daphne Zohar and team, and Steve Paul for an amazing IPO to fuel new drugs for mental health and brain disorders. ARCH invested early here because of the team, platform, and clinical need.
Cue Biopharma Licenses Ascendant-221 From Ascendant Health Sciences in a ~$691.5M Deal
Cue Biopharma announced an exclusive license with Ascendant Health Sciences for Ascendant-221, an anti‑IgE monoclonal antibody aimed at allergic diseases. The agreement grants Cue worldwide rights, except Greater China, in exchange for a $15 million upfront payment and up to $676.5 million...
T‑cell Vesicles Deliver DNA, Converting Cold Tumors Hot
In cancer, activated T cells release abundant extracellular vesicles that transfer DNA to the nucleus of tumor and immune (dendritic) cells, turning tumors from cold to hot. An immunotherapy in the works. @Cancer_Cell https://t.co/mHcahijOJC https://t.co/oPT6d7lrFM https://t.co/I0egYxZold
Early Trial RNA‑seq Data: Exciting Yet Requires Caution
🧵 You just got your hands on early clinical trial RNA-seq data. Excited? You should also be cautious. Here's why. 👇 https://t.co/GjA8XIYcVQ
Approaches to Reducing Toxicity and Side Effects in Cell and Gene Therapy
Cell and gene therapies are expanding rapidly, with the market projected to exceed $9 billion in 2025 and grow over 15% annually through 2035. Safety remains a hurdle, prompting multiple strategies to curb cytokine release syndrome (CRS) and related toxicities. Companies...
Biotech IPOs Surge, Exposing Wall St Underestimation
Three biotech IPOs this week. Each one raised its number of shares and priced atop range. Suggests that Wall St is slightly underestimating investor interest in new biotech issues.
AI Chatbots Capture Poorer Symptom Detail than Doctors
Symptoms reported to an AI chatbot were of lesser quality than reported to a physician, results of a randomized trial of 500 participants across multiple models https://t.co/WXP4R3y9HA https://t.co/l2hLT76AJB
FDA's ODAC Delivers One Loss, One Win for AstraZeneca
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 6‑3 against AstraZeneca’s oral SERD camizestrant in combination with CDK‑4/6 inhibitors for first‑line HR‑positive, HER2‑negative breast cancer with ESR1 mutations, citing a lack of overall survival benefit despite a 56% progression‑free survival...
FDA Approves First Non‑antipsychotic for Dementia Agitation
⚕️ FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia 🔗https://t.co/cPNtkiSXBs 🌐 #DHPSP #Pharma #Healthcare https://t.co/KsBKc45ekk
FDA Taps Szarama as Acting CBER Director as Prasad’s Tumultuous Tenure Ends
Vinay Prasad is leaving his role as head of the FDA’s Center for Biologics Evaluation and Research (CBER) after a contentious tenure that included the Elevidys gene‑therapy shutdown and multiple rare‑disease therapy rejections. The agency has named his deputy, biophysicist Katherine Szarama,...
Gene Editing at Scale, Clinic Seeks Generalizable Therapies
Integrated DNA Technologies helped deliver a CRISPR therapy that rescued baby KJ Muldoon from a fatal urea‑cycle disorder, proving gene editing can correct a single disease‑causing mutation. The success highlights the field’s next hurdle: scaling personalized edits for disorders with...
Smarter AAVs Drive Gene Therapy’s Next Chapter
Gene therapy’s growth is hampered by AAV manufacturing bottlenecks, safety concerns, and high costs, prompting a wave of innovations across bioprocessing, analytics, and vector design. Companies like Thermo Fisher, PackGene, Catalent, and Asimov are deploying design‑space modeling, high‑throughput purification, and...
What’s Next in the Evolution of Standards for Biologics Development
The United States Pharmacopeia (USP) is redefining how documentary standards support biologics, moving from product‑specific monographs toward a hybrid model that blends platform‑based chapters, emerging standards, and analytical reference materials. This shift addresses the growing complexity of monoclonal antibodies, ADCs,...